The Role of PET in Salvage Therapy for Prostate Cancer-Reference-Cited by-同舟云学术

The Role of PET in Salvage Therapy for Prostate Cancer

Published:2020-11-24 Issue: Volume: Page:89-114
ISSN:
Container-title:Salvage Therapy for Prostate Cancer
language:
Short-container-title:

Author:

Goonewardene Sanchia S.,Persad Raj,Albala David,Cahill Declan

Publisher

Springer International Publishing

Link

http://link.springer.com/content/pdf/10.1007/978-3-030-57181-8_9

Reference67 articles.

1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the Prisma statement. BMJ (Online). 2009;339(7716):332–6.

2. Mays N, Pope C, Popay J. Systematically reviewing qualitative and quantitative evidence to inform management and policy-making in the health field. J Health Serv Res Pol. 2005;10(Suppl. 1):6–20.

3. Herlemann A, Kretschmer A, Buchner A, Karl A, Tritschler S, El-Malazi L, Fendler WP, et al. Salvage lymph node dissection after (68)Ga-PSMA or (18)F-FEC PET/CT for nodal recurrence in prostate cancer patients. Oncotarget. 2017;8(48):84180–92.

4. Fossati N, Scarcella S, Gandaglia G, Suardi N, Robesti D, Boeri L, Karnes RJ, et al. Underestimation of PET/CT scan in assessing tumour burden of men with nodal recurrence from prostate cancer: head-to-head comparison of (68)Ga-PSMA and (11)C-choline in a large, multi-institutional series of extended salvage lymph node dissections. J Urol. 2020;204(2):296–302. https://doi.org/10.1097/JU.0000000000000800.

5. Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler K, et al. (68)Ga-PSMA-11 PET/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a Psa level of less than 1.0 ng/mL: impact on salvage radiotherapy planning. J Nucl Med. 2018;59(2):230–7.